Financial Position - Climb Bio has approximately $218 million in cash, cash equivalents, and marketable securities as of September 30, 2024, expected to fund operations through 2027[8]. Clinical Trials and Development - In the Phase 1b study of budoprutug for primary membranous nephropathy (pMN), 60% of patients achieved complete remission of proteinuria[5]. - Budoprutug demonstrated complete and sustained B-cell depletion in all patients, with undetectable levels of B-cells after just two doses as low as 100 mg[5]. - The company plans to initiate Phase 1b clinical trials in systemic lupus erythematosus (SLE) and immune thrombocytopenia (ITP) in the first half of 2025, subject to regulatory clearance[6][7]. - Budoprutug has been successfully formulated above 175 mg/ml for a potential subcutaneous dosing form, with non-clinical data expected in the first half of 2025[4]. - The strategic development of budoprutug targets three opportunity sets: IgG4-mediated diseases, IgG1-3 diseases affecting single organ systems, and complex systemic diseases[3]. - The company aims to advance the pMN clinical program to late-phase development expected in 2025[8]. - A single-arm, open-label study for chronic ITP will include a "treat-to-target" approach for personalized redosing based on individual patient needs[7]. - The Phase 1b trial in SLE will utilize serum biomarkers to accelerate proof-of-concept and optimize dosing[6]. Product Potential - Climb Bio emphasizes the potential of budoprutug as a differentiated anti-CD19 monoclonal antibody for B-cell mediated diseases[3].
Eliem Therapeutics(ELYM) - 2024 Q3 - Quarterly Results